scholarly article | Q13442814 |
P2093 | author name string | Damiano Rondelli | |
Ilangovan Raju | |||
Anna Ahn | |||
Sandeep Jain | |||
Sapna Tibrewal | |||
Ji-Eun Kwon | |||
Yi-Fan Chen | |||
Shilpa Gulati | |||
Bayasgalan Surenkhuu | |||
Anubhav Pradeep | |||
Christine Mun | |||
Seungwon An | |||
Morgan Buwick | |||
Nour Atassi | |||
P2860 | cites work | Reliability and validity of the Ocular Surface Disease Index | Q73801624 |
Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88 | Q74342588 | ||
New insight into dry eye inflammation | Q85715473 | ||
Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications | Q87417489 | ||
n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease | Q88350776 | ||
Dornase alfa for cystic fibrosis | Q24185927 | ||
Extracellular DNA traps in allergic, infectious, and autoimmune diseases | Q26825623 | ||
NETs and CF Lung Disease: Current Status and Future Prospects | Q26864316 | ||
Neutrophil extracellular traps kill bacteria | Q27860996 | ||
Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease | Q28266421 | ||
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide | Q29619485 | ||
Extracellular histones are major mediators of death in sepsis | Q34019901 | ||
Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones | Q34184548 | ||
Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. | Q34206399 | ||
Hyperosmolar stress induces neutrophil extracellular trap formation: implications for dry eye disease | Q34677680 | ||
Neutrophil extracellular traps: double-edged swords of innate immunity | Q36226113 | ||
Trashing the genome: the role of nucleases during apoptosis | Q36231781 | ||
Ocular surface extracellular DNA and nuclease activity imbalance: a new paradigm for inflammation in dry eye disease | Q36474926 | ||
The origin and properties of extracellular DNA: from PAMP to DAMP. | Q37047827 | ||
Tear fluid extracellular DNA: diagnostic and therapeutic implications in dry eye disease | Q37386334 | ||
Minimal clinically important difference for the ocular surface disease index | Q37672025 | ||
Structural modification of DNA--a therapeutic option in SLE? | Q37947116 | ||
Comparative biochemical properties of vertebrate deoxyribonuclease I. | Q38033968 | ||
Dornase alfa (Pulmozyme). | Q38044650 | ||
Neutrophil extracellular traps as a new paradigm in innate immunity: friend or foe? | Q38127783 | ||
Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting | Q38151227 | ||
Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis | Q38490506 | ||
TFOS DEWS II pathophysiology report | Q38652987 | ||
TFOS DEWS II Definition and Classification Report. | Q38665717 | ||
The development of validated bulbar redness grading scales. | Q39824014 | ||
Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. | Q40948258 | ||
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. | Q42227558 | ||
Inhibition of deoxyribonuclease I by actin is to protect cells from premature cell death | Q42828776 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | clinical trial | Q30612 |
placebo | Q269829 | ||
eye disease | Q3041498 | ||
phase I clinical trial | Q5452194 | ||
Nets | Q28838095 | ||
P304 | page(s) | 10 | |
P577 | publication date | 2019-05-01 | |
P1433 | published in | Translational vision science & technology | Q27724547 |
P1476 | title | A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease | |
P478 | volume | 8 |
Search more.